Navigation Links
FDA's Just Approved Monthly Drug Treatment, Vivitrol Could Be 'Game Changer,' Says Country's Largest Drug Treatment Recovery President, CRC's Jerry Rhodes; Provides Addicts 'One Decision A Month Instead of 30'
Date:10/12/2010

WASHINGTON and CUPERTINO, Calif., Oct. 12 /PRNewswire-USNewswire/ -- "The FDA's just approved monthly drug treatment with Vivitrol could be a game changer," said the country's largest substance abuse treatment provider, CRC Health Group, Recovery Division President Jerry Rhodes, whose company has 140 facilities across the country. Rhodes said the new treatment regimen "will provide addicts seeking help one decision a month instead of 30, and a new way to reduce or eliminate relapse. We are pleased to play a part in rolling out this potentially life-saving treatment."

Former U.S. Drug Czar, General Barry McCaffrey, now on CRC's Board, congratulated the FDA and CRC "for adopting a science-based new approach to reduce the national drug treatment gap. Addicts who in the past have been reluctant to seek treatment will be far more likely with a once-a-month opportunity to stop their craving. This is another important new tool in treatment."

Rhodes and McCaffrey offered "thanks and congratulations" to Alkermes Inc for developing and providing the medication approved today by the FDA and to be used by CRC facilities.

Rhodes stated that CRC has been utilizing Vivitrol to treat alcoholism "for years with extremely positive results" and is now in the process of developing the protocols and formulations for therapy for opiate patients. He stated that "every patient is an individual case. Vivitrol will be among the treatment options doctors will now have available, in addition to already existing Methadone and Suboxone (buprenorphine). In all cases, counseling and monitoring are a crucial part of treatment."

McCaffrey added, "The abuse of opioids like prescription pain medications and heroin is on the rise. Prescription drug abuse has tripled in the past decade – it's the new heroin. Nearly 16 million Americans ages 12 and older misused or abused prescription drugs or heroin in 2008 according to SAMHSA's National Survey on Drug Use and Health."

Contact: Bob Weiner 301-283-0821/202-306-1200 and Kristen Hayes 949-589-1765/562-229-2204


'/>"/>
SOURCE Robert Weiner Associates and CRC Health Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):